Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Master Protocol Continuation Study
NCT05059522Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
A Phase 3 trial of avelumab in malignant neoplasms (advanced stage), non-small cell lung cancer (NSCLC), ovarian cancer, urothelial carcinoma (UC), solid tumor, sponsored by Pfizer. Started Sep 2021; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
malignant neoplasms (advanced stage)non-small cell lung cancer (NSCLC)ovarian cancerurothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT05059522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059522.